Moleculin Biotech, Inc.
MBRX· Nasdaq
MBRXMoleculin Biotech, Inc.
Filed Aug 13, 2026 · 10-Q · 44 days after period end · 0001437749-26-027688
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.64M | -$17.81M | -$6.02M | -$5.98M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Moleculin Biotech, Inc. · CIK 1659617 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end
